{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:06:03Z","timestamp":1790726763774,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:00:00Z","timestamp":1610755200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T00:00:00Z","timestamp":1610755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japanese Society for the Promotion of Science","doi-asserted-by":"crossref","award":["17K10541"],"award-info":[{"award-number":["17K10541"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10549-020-06033-2","type":"journal-article","created":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T08:02:42Z","timestamp":1610784162000},"page":"37-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells"],"prefix":"10.1007","volume":"186","author":[{"given":"Takaaki","family":"Oba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanori","family":"Matoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6430-0307","authenticated-orcid":false,"given":"Ken-ichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,16]]},"reference":[{"key":"6033_CR1","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","volume":"19","author":"M Bonotto","year":"2014","unstructured":"Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, Minisini AM, Andreetta C, Mansutti M, Pisa FE, Fasola G, Puglisi F (2014) Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 19:608\u2013615. https:\/\/doi.org\/10.1634\/theoncologist.2014-0002","journal-title":"Oncologist"},{"key":"6033_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10549-016-4080-9","volume":"161","author":"WD den Brok","year":"2017","unstructured":"den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA (2017) Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed. Breast Cancer Res Treat 161:549\u2013556. https:\/\/doi.org\/10.1007\/s10549-016-4080-9","journal-title":"Breast Cancer Res Treat"},{"key":"6033_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clbc.2012.09.002","volume":"13","author":"E Montagna","year":"2013","unstructured":"Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, Balduzzi A, Galimberti V, Veronesi P, Luini A, Pruneri G, Bottiglieri L, Mastropasqua MG, Goldhirsch A, Viale G, Colleoni M (2013) Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer 13:31\u201339. https:\/\/doi.org\/10.1016\/j.clbc.2012.09.002","journal-title":"Clin Breast Cancer"},{"key":"6033_CR4","doi-asserted-by":"publisher","first-page":"e1000279","DOI":"10.1371\/journal.pmed.1000279","volume":"7","author":"FM Blows","year":"2010","unstructured":"Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkila P, Heikkinen T, Nevanlinna H, Akslen LA, Begin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, Garcia-Closas M, Caldas C, Pharoah PD, Huntsman D (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7:e1000279. https:\/\/doi.org\/10.1371\/journal.pmed.1000279","journal-title":"PLoS Med"},{"key":"6033_CR5","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938\u20131948. https:\/\/doi.org\/10.1056\/NEJMra1001389","journal-title":"N Engl J Med"},{"key":"6033_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346\u2013352. https:\/\/doi.org\/10.1038\/nature10983","journal-title":"Nature"},{"key":"6033_CR7","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1535-7163.Mct-04-0345","volume":"4","author":"MA Jordan","year":"2005","unstructured":"Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086\u20131095. https:\/\/doi.org\/10.1158\/1535-7163.Mct-04-0345","journal-title":"Mol Cancer Ther"},{"key":"6033_CR8","first-page":"1509","volume":"27","author":"J Liu","year":"2007","unstructured":"Liu J, Towle MJ, Cheng H, Saxton P, Reardon C, Wu J, Murphy EA, Kuznetsov G, Johannes CW, Tremblay MR, Zhao H, Pesant M, Fang FG, Vermeulen MW, Gallagher BM Jr, Littlefield BA (2007) In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res 27:1509\u20131518","journal-title":"Anticancer Res"},{"key":"6033_CR9","doi-asserted-by":"publisher","first-page":"7135","DOI":"10.1158\/0008-5472.Can-09-1618","volume":"69","author":"T Tsuji","year":"2009","unstructured":"Tsuji T, Ibaragi S, Hu GF (2009) Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 69:7135\u20137139. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-1618","journal-title":"Cancer Res"},{"key":"6033_CR10","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J (2014) Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer 110:1497\u20131505. https:\/\/doi.org\/10.1038\/bjc.2014.80","journal-title":"Br J Cancer"},{"key":"6033_CR11","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1172\/jci65416","volume":"123","author":"NE Bhola","year":"2013","unstructured":"Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M, Stanford J, Cook RS, Arteaga CL (2013) TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 123:1348\u20131358. https:\/\/doi.org\/10.1172\/jci65416","journal-title":"J Clin Invest"},{"key":"6033_CR12","first-page":"277","volume":"31","author":"H Kajiyama","year":"2007","unstructured":"Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, Kikkawa F (2007) Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31:277\u2013283","journal-title":"Int J Oncol"},{"issue":"33","key":"6033_CR13","doi-asserted-by":"publisher","first-page":"22986","DOI":"10.18632\/oncotarget.25184","volume":"9","author":"T Oba","year":"2018","unstructured":"Oba T, Ito KI (2018) Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition. Oncotarget 9(33):22986\u201323002. https:\/\/doi.org\/10.18632\/oncotarget.25184","journal-title":"Oncotarget"},{"key":"6033_CR14","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, Tohyama O, Uehara T, Kimura T, Watanabe H, Asano M, Kawano S, Tizon X, McCracken PJ, Matsui J, Aoshima K, Nomoto K, Oda Y (2014) Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 105:1334\u20131342. https:\/\/doi.org\/10.1111\/cas.12488","journal-title":"Cancer Sci"},{"key":"6033_CR15","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.21873\/anticanres.12541","volume":"38","author":"W Goto","year":"2018","unstructured":"Goto W, Kashiwagi S, Asano Y, Takada K, Morisaki T, Fujita H, Takashima T, Ohsawa M, Hirakawa K, Ohira M (2018) Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer. Anticancer Res. 38:2929\u20132938. https:\/\/doi.org\/10.21873\/anticanres.12541","journal-title":"Anticancer Res."},{"key":"6033_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/312237a0","volume":"312","author":"T Mitchison","year":"1984","unstructured":"Mitchison T, Kirschner M (1984) Dynamic instability of microtubule growth. Nature 312:237\u2013242","journal-title":"Nature"},{"key":"6033_CR17","doi-asserted-by":"publisher","first-page":"22516","DOI":"10.1074\/jbc.M113.489328","volume":"288","author":"J Asthana","year":"2013","unstructured":"Asthana J, Kapoor S, Mohan R, Panda D (2013) Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells. J Biol Chem 288:22516\u201322526. https:\/\/doi.org\/10.1074\/jbc.M113.489328","journal-title":"J Biol Chem"},{"key":"6033_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.tcb.2014.10.004","volume":"25","author":"Y Song","year":"2015","unstructured":"Song Y, Brady ST (2015) Post-translational modifications of tubulin: pathways to functional diversity of microtubules. Trends Cell Biol 25:125\u2013136. https:\/\/doi.org\/10.1016\/j.tcb.2014.10.004","journal-title":"Trends Cell Biol"},{"key":"6033_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/417455a","volume":"417","author":"C Hubbert","year":"2002","unstructured":"Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417:455\u2013458. https:\/\/doi.org\/10.1038\/417455a","journal-title":"Nature"},{"key":"6033_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/PPO.0b013e31803c72ba","volume":"13","author":"JM Mehnert","year":"2007","unstructured":"Mehnert JM, Kelly WK (2007) Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 13:23\u201329. https:\/\/doi.org\/10.1097\/PPO.0b013e31803c72ba","journal-title":"Cancer J"},{"key":"6033_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.canlet.2009.01.002","volume":"280","author":"VM Richon","year":"2009","unstructured":"Richon VM, Garcia-Vargas J, Hardwick JS (2009) Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280:201\u2013210. https:\/\/doi.org\/10.1016\/j.canlet.2009.01.002","journal-title":"Cancer Lett"},{"key":"6033_CR22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3816\/CLM.2009.n.082","volume":"9","author":"M Duvic","year":"2009","unstructured":"Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-Rodriguez C, Geskin LJ (2009) Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 9:412\u2013416. https:\/\/doi.org\/10.3816\/CLM.2009.n.082","journal-title":"Clin Lymphoma Myeloma"},{"key":"6033_CR23","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s10495-017-1364-4","volume":"22","author":"M Cosenza","year":"2017","unstructured":"Cosenza M, Civallero M, Marcheselli L, Sacchi S, Pozzi S (2017) Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine. Apoptosis 22:827\u2013840. https:\/\/doi.org\/10.1007\/s10495-017-1364-4","journal-title":"Apoptosis"},{"key":"6033_CR24","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1158\/1078-0432.ccr-16-2526","volume":"23","author":"DT Vogl","year":"2017","unstructured":"Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, Supko JG, Tamang D, Yang M, Jones SS, Wheeler C, Markelewicz RJ, Lonial S (2017) Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res 23:3307\u20133315. https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-2526","journal-title":"Clin Cancer Res"},{"key":"6033_CR25","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3892\/or.2016.5340","volume":"37","author":"U Peng","year":"2017","unstructured":"Peng U, Wang Z, Pei S, Ou Y, Hu P, Liu W, Song J (2017) ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation. Oncol Rep 37:1270\u20131276. https:\/\/doi.org\/10.3892\/or.2016.5340","journal-title":"Oncol Rep"},{"key":"6033_CR26","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1677\/erc-07-0096","volume":"14","author":"MG Catalano","year":"2007","unstructured":"Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G (2007) Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 14:839\u2013845. https:\/\/doi.org\/10.1677\/erc-07-0096","journal-title":"Endocr Relat Cancer"},{"key":"6033_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ijc.24759","volume":"126","author":"TK Owonikoko","year":"2010","unstructured":"Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA (2010) Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer 126:743\u2013755. https:\/\/doi.org\/10.1002\/ijc.24759","journal-title":"Int J Cancer"},{"key":"6033_CR28","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1158\/1535-7163.Mct-06-0209","volume":"5","author":"SC Dowdy","year":"2006","unstructured":"Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC, Jiang SW (2006) Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 5:2767\u20132776. https:\/\/doi.org\/10.1158\/1535-7163.Mct-06-0209","journal-title":"Mol Cancer Ther"},{"key":"6033_CR29","doi-asserted-by":"publisher","first-page":"e29085","DOI":"10.1371\/journal.pone.0029085","volume":"6","author":"V Zuco","year":"2011","unstructured":"Zuco V, De Cesare M, Cincinelli R, Nannei R, Pisano C, Zaffaroni N, Zunino F (2011) Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo. PLoS ONE 6:e29085. https:\/\/doi.org\/10.1371\/journal.pone.0029085","journal-title":"PLoS ONE"},{"key":"6033_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10549-018-4815-x","volume":"171","author":"H Ono","year":"2018","unstructured":"Ono H, Sowa Y, Horinaka M, Iizumi Y, Watanabe M, Morita M, Nishimoto E, Taguchi T, Sakai T (2018) The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway. Breast Cancer Res Treat 171:43\u201352. https:\/\/doi.org\/10.1007\/s10549-018-4815-x","journal-title":"Breast Cancer Res Treat"},{"issue":"43","key":"6033_CR31","doi-asserted-by":"publisher","first-page":"70011","DOI":"10.18632\/oncotarget.11727","volume":"7","author":"T Oba","year":"2016","unstructured":"Oba T, Izumi H, Ito KI (2016) ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines. Oncotarget 7(43):70011\u201370027. https:\/\/doi.org\/10.18632\/oncotarget.11727","journal-title":"Oncotarget"},{"key":"6033_CR32","first-page":"351","volume":"48","author":"Y Kano","year":"1988","unstructured":"Kano Y, Ohnuma T, Okano T, Holland JF (1988) Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res 48:351\u2013356","journal-title":"Cancer Res"},{"key":"6033_CR33","doi-asserted-by":"publisher","first-page":"8837","DOI":"10.1158\/1078-0432.ccr-05-0945","volume":"11","author":"T Fujita","year":"2005","unstructured":"Fujita T, Ito K, Izumi H, Kimura M, Sano M, Nakagomi H, Maeno K, Hama Y, Shingu K, Tsuchiya S, Kohno K, Fujimori M (2005) Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res 11:8837\u20138844. https:\/\/doi.org\/10.1158\/1078-0432.ccr-05-0945","journal-title":"Clin Cancer Res"},{"key":"6033_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13058-015-0658-0","volume":"17","author":"P Putcha","year":"2015","unstructured":"Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, Califano A, Silva J (2015) HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Res 17:149. https:\/\/doi.org\/10.1186\/s13058-015-0658-0","journal-title":"Breast Cancer Res"},{"key":"6033_CR35","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nrm1260","volume":"4","author":"S Westermann","year":"2003","unstructured":"Westermann S, Weber K (2003) Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol 4:938\u2013947. https:\/\/doi.org\/10.1038\/nrm1260","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6033_CR36","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.Ccr-16-2622","volume":"23","author":"AM Torres-Adorno","year":"2017","unstructured":"Torres-Adorno AM, Lee J, Kogawa T, Ordentlich P, Tripathy D, Lim B, Ueno NT (2017) Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. Clin Cancer Res 23:4780\u20134792. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-2622","journal-title":"Clin Cancer Res"},{"issue":"2","key":"6033_CR37","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.18632\/oncotarget.13738","volume":"8","author":"P Huang","year":"2017","unstructured":"Huang P, Almeciga-Pinto I, Jarpe M, van Duzer JH, Mazitschek R, Yang M, Jones SS, Quayle SN (2017) Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models. Oncotarget 8(2):2694\u20132707. https:\/\/doi.org\/10.18632\/oncotarget.13738","journal-title":"Oncotarget"},{"key":"6033_CR38","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1158\/0008-5472.Can-08-3458","volume":"69","author":"K Azuma","year":"2009","unstructured":"Azuma K, Urano T, Horie-Inoue K, Hayashi S, Sakai R, Ouchi Y, Inoue S (2009) Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells. Cancer Res 69:2935\u20132940. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-3458","journal-title":"Cancer Res"},{"key":"6033_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1158\/0008-5472.Can-13-3563","volume":"75","author":"AE Boggs","year":"2015","unstructured":"Boggs AE, Vitolo MI, Whipple RA, Charpentier MS, Goloubeva OG, Ioffe OB, Tuttle KC, Slovic J, Lu Y, Mills GB, Martin SS (2015) alpha-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration. Cancer Res 75:203\u2013215. https:\/\/doi.org\/10.1158\/0008-5472.Can-13-3563","journal-title":"Cancer Res"},{"key":"6033_CR40","doi-asserted-by":"publisher","first-page":"10166","DOI":"10.1073\/pnas.0603704103","volume":"103","author":"H Xiao","year":"2006","unstructured":"Xiao H, Verdier-Pinard P, Fernandez-Fuentes N, Burd B, Angeletti R, Fiser A, Horwitz SB, Orr GA (2006) Insights into the mechanism of microtubule stabilization by Taxol. Proc Natl Acad Sci U S A 103:10166\u201310173. https:\/\/doi.org\/10.1073\/pnas.0603704103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6033_CR41","doi-asserted-by":"publisher","first-page":"6615","DOI":"10.1158\/1078-0432.Ccr-11-1807","volume":"17","author":"S Jain","year":"2011","unstructured":"Jain S, Vahdat LT (2011) Eribulin mesylate. Clin Cancer Res 17:6615\u20136622. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-1807","journal-title":"Clin Cancer Res"},{"key":"6033_CR42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0005-2736(99)00161-3","volume":"1461","author":"I Klein","year":"1999","unstructured":"Klein I, Sarkadi B, Varadi A (1999) An inventory of the human ABC proteins. Biochim Biophys Acta 1461:237\u2013262","journal-title":"Biochim Biophys Acta"},{"key":"6033_CR43","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.canlet.2018.01.021","volume":"421","author":"YF Fan","year":"2018","unstructured":"Fan YF, Zhang W, Zeng L, Lei ZN, Cai CY, Gupta P, Yang DH, Cui Q, Qin ZD, Chen ZS, Trombetta LD (2018) Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Lett 421:186\u2013198. https:\/\/doi.org\/10.1016\/j.canlet.2018.01.021","journal-title":"Cancer Lett"},{"issue":"55","key":"6033_CR44","doi-asserted-by":"publisher","first-page":"93785","DOI":"10.18632\/oncotarget.21078","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Kumar P, Anreddy N, Zhang YK, Wang YJ, Chen Y, Talele TT, Gupta K, Trombetta LD, Chen ZS (2017) Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies. Oncotarget 8(55):93785\u201393799. https:\/\/doi.org\/10.18632\/oncotarget.21078","journal-title":"Oncotarget"},{"key":"6033_CR45","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02151-17","author":"NN Nickerson","year":"2018","unstructured":"Nickerson NN, Jao CC, Xu Y, Quinn J, Skippington E, Alexander MK, Miu A, Skelton N, Hankins JV, Lopez MS, Koth CM, Rutherford S, Nishiyama M (2018) A Novel Inhibitor of the LolCDE ABC Transporter Essential for Lipoprotein Trafficking in Gram-Negative Bacteria. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02151-17","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-06033-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-020-06033-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-06033-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T08:05:17Z","timestamp":1615190717000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-020-06033-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,16]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["6033"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-06033-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.23568\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,16]]},"assertion":[{"value":"4 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Medical Ethics Committee on Clinical Investigation of Shinshu University (No. 3819). All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}